Loading clinical trials...
Loading clinical trials...
The purpose of this study is to evaluate the safety, PK and efficacy of RP6530, a dual PI3K delta/gamma inhibitor in patients with relapsed and refractory T-cell Lymphoma.
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
Rhizen Pharmaceuticals SA
NCT06561048 · Peripheral T-Cell Lymphoma, Not Otherwise Specified, Angioimmunoblastic T-cell Lymphoma, and more
NCT06947967 · Lymphoma, T-Cell, Peripheral
NCT04998331 · Hodgkin Disease, Lymphoma, T-Cell, Cutaneous
NCT03789864 · Lymphoma, T-Cell, Cutaneous, Mycosis Fungoides
NCT05137847 · Lymphoma, T-cell, Peripheral, Lymphoma, T-cell, Cutaneous
City of Hope
Duarte, California
Chao Family Comprehensive Cancer Center University of California Irvine
Orange, California
University of Colorado Cancer Center
Aurora, Colorado
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions